Hun Ju Lee

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

40h-index5.9kcitations287works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(187), CAR-T cell therapy research(86), Chronic Lymphocytic Leukemia Research(68), Viral-associated cancers and disorders(41), CNS Lymphoma Diagnosis and Treatment(31)

Publications287 total

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients
Blood·2025
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Blood·2025Open Access
Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib
Blood·2025Open Access
Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis
Blood·2025Open Access
Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial
Blood·2025Open Access
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Blood·2025Open Access
A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)
Blood·2025
POSTER: HL-1025 Circulating Tumor DNA (ctDNA) Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma (cHL) Treated With a Combination of Brentuximab Vedotin (BV) and Nivolumab
Clinical Lymphoma Myeloma & Leukemia·2025
HL-1025: Circulating Tumor DNA (ctDNA) Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma (cHL) Treated With a Combination of Brentuximab Vedotin (BV) and Nivolumab
Clinical Lymphoma Myeloma & Leukemia·2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Blood Advances·2025Open Access
Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.
Journal of Clinical Oncology·2025· 1 cited
An Analysis of the Actual Status of Doping Attitude in South Korean Female Bodybuilders in Bodybuilding Bikini
Iranian Journal of Public Health·2025Open Access
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results
Blood Advances·2025· 2 citedOpen Access
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
HemaSphere·2025· 2 citedOpen Access
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2025
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma
Blood·2024· 12 cited
Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Blood·2024· 5 citedOpen Access
Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)
Blood·2024· 2 citedOpen Access
Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
Blood·2024Open Access
A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
Blood·2024· 3 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Jason R. Westin(24), Michael Wang(23), Loretta J. Nastoupil(23), Luis Fayad(23), Sattva S. Neelapu(22), Felipe Samaniego(18), Nathan Fowler(17), Sairah Ahmed(15), Christopher R. Flowers(15), Maria Alma Rodriguez(14), Raphaël Steiner(14), Fredrick B. Hagemeister(13), Chelsea C. Pinnix(13), Ranjit Nair(13), Swaminathan P. Iyer(13), Yasuhiro Oki(11), Michelle A. Fanale(11), Paolo Strati(11), Jorge Romaguera(9), Preetesh Jain(8)